Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001
about
RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials.Genistein mediates the selective radiosensitizing effect in NSCLC A549 cells via inhibiting methylation of the keap1 gene promoter regionA novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells.Hypoxic conditions increases H₂S-induced ER stress in A2870 cells.Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity.The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry.RRx-001 protects against cisplatin-induced toxicities.Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors.No patient left behind: The promise of immune priming with epigenetic agents.MIND4-17 protects retinal pigment epithelium cells and retinal ganglion cells from UV.Proteasome-associated deubiquitinases and cancer.MicroRNA-200a activates Nrf2 signaling to protect osteoblasts from dexamethasone.Activation of Nrf2 by MIND4-17 protects osteoblasts from hydrogen peroxide-induced oxidative stress.The dichotomous role of H2S in cancer cell biology? Déjà vu all over again.Activation of AMPK by OSU53 protects spinal cord neurons from oxidative stress.A Review of Clinical Radioprotection and Chemoprotection for Oral Mucositis.
P2860
Q30010522-71DA812B-73EF-4CBE-8F73-3D5457E632D1Q37317230-2D245A73-369F-46EC-AE93-5DCF33F9F117Q37389377-2343DC1E-359D-42DA-BA44-6E359E7F5B47Q38794896-8A98F365-98A6-4296-B774-2E8F1EFEC222Q38812418-06D3D203-D2B8-4407-BC1F-C2BB4A63ABA8Q40349579-8769011B-63F4-4EEA-A5B5-3E30DBA22BE4Q46154170-B6D3B303-35E8-4980-9E63-50131E7C7CF8Q46237277-42E4E88A-E80B-476A-BCE7-E98CE7477D2EQ46665179-57113650-949A-42D5-8FBD-25794F65E83BQ47120331-C71A16E3-BAD4-4A3F-9E4D-FA01352B2274Q47161331-6C5686C9-A39A-47EA-A8E7-C77BA58ED009Q47167976-D66583BB-78CD-4690-94E5-9D089D0492C9Q47211711-9BC24F22-4543-46EF-953C-E962B382B73FQ49346285-3D233A0E-4E2F-41AD-B60A-B997C7AB065BQ49948740-38A30290-3A16-43DA-B70C-4101DE23AA99Q52560942-1B2C7A64-A0A4-43F8-8075-58B9B3B1B3D9
P2860
Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001
@en
type
label
Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001
@en
prefLabel
Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001
@en
P2093
P2860
P356
P1433
P1476
Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001
@en
P2093
Bryan Oronsky
Donna M Peehl
Jan Scicinski
Ramasamy Paulmurugan
Shoucheng Ning
Susan J Knox
Thillai Veerapazham Sekar
P2860
P304
21547-21556
P356
10.18632/ONCOTARGET.4249
P407
P577
2015-06-04T00:00:00Z